Comparative Pharmacology
Head-to-head clinical analysis: XALATAN versus ZIOPTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: XALATAN versus ZIOPTAN.
XALATAN vs ZIOPTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Latanoprost is a prostaglandin F2α analogue that reduces intraocular pressure by increasing the outflow of aqueous humor through the uveoscleral pathway.
ZIOPTAN (tafluprost) is a prostaglandin analog that reduces intraocular pressure by increasing the outflow of aqueous humor through the uveoscleral pathway.
One drop (1.5 mg/mL) in the affected eye(s) once daily in the evening.
250 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life of latanoprost acid is approximately 17 minutes; clinically, intraocular pressure reduction persists for 24 hours due to long receptor residence time.
Terminal elimination half-life is approximately 2.8 to 4.5 hours in patients with normal renal function; no clinically significant accumulation occurs with twice-daily dosing.
Renal (approximately 50% as metabolites, <1% as unchanged drug); biliary/fecal (remainder).
Primarily renal excretion of unchanged drug (approximately 70-80% of an administered dose recovered in urine over 48 hours); biliary/fecal excretion accounts for 13% to 20% as parent drug and metabolites.
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog